Peer Reviewed
Perspectives on diabetes

A1c and CVD – how low to go?

Pat Phillips
The target levels of glycosylated haemoglobin (A1c) for people with type 2 diabetes have been questioned following the findings of three recent trials of tight glycaemic control.
Key Points

    Tight treatment targets for people with diabetes have come into question with three recently published studies identifying no cardiovascular benefit of tight glycaemic control and one of these also demonstrating an increase in mortality rate. In all three studies, glycosylated haemoglobin (A1c) levels were significantly reduced in individuals with or at high risk of cardiovascular disease (CVD). These studies have an impact on the target levels of A1c recommended to people with type 2 diabetes.

Purchase the PDF version of this article
Already a subscriber?